Description
The Global Neoantigen Cancer Vaccine Market is projected to develop with a CAGR of 54.19% throughout the forecast period and is expected to reach USD 1754 million by 2027 from USD 804 Million in 2020. Rapid technological improvements and infrastructural trends withinside the healthcare industry are driving the growth of the neoantigen cancer vaccines market. Increased investment by government and healthcare professionals is also expected to contribute to the global growth of the neoantigen cancer vaccines market in the coming years. Furthermore, the increase in cancer cases is expected to drive market growth till 2028. The prevalence of cancer is increasing all over the world. In addition, significant external funding is required to complete the research and development project. These elements stimulate the market for neoantigen cancer vaccines and performance-based pricing that hinders the global market growth.
